By Shania Kennedy
May 06, 2024 – Researchers from the University of Texas (UT) Southwestern Medical Center have developed a computational tool to predict breast cancer immunotherapy response by analyzing how cancer and immune cells interact.
The…
Xaira Therapeutics, an AI-enabled drug discovery and development company, announced its launch with more than $1 billion in capital. The biotechnology company is a joint incubation by ARCH Venture Partners and Foresite Labs, the lead…
Continue Reading
Progress in sequencing technologies and clinical experiments has revolutionized immunotherapy on solid and hematologic malignancies. However, the benefits of immunotherapy are limited to specific patient subsets, posing challenges for broader application. To improve its…
Continue Reading
Welcome to the January edition of Digital Health Digest on our YouTube channel! Dive into the latest and most exciting advancements in digital healthcare, from cutting-edge diagnostic tools to innovative telehealth services. In this…
Continue Reading
What You Should Know:
– 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to…
Continue Reading
New adjunct specialty facilities in India’s leading health institutions are advancing precision medicine in the country through AI. The Apollo Cancer Centre (ACC) in Bengaluru has recently opened what could be the country’s first Precision…
Continue Reading
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the…
Continue Reading
Penn Medicine’s iStar emerges as a game-changing AI tool, developed by Perelman School of Medicine experts. This revolutionary application, short for Inferring Super-Resolution Tissue Architecture, presents a paradigm shift in oncology diagnostics. iStar delves…
Continue Reading
GE HealthCare’s AI can accurately predict patient responses to immunotherapy, as demonstrated in collaborative studies with VUMC and UME. The models, showcasing 70-80% accuracy, may guide more personalized treatment decisions, potentially minimizing side effects…
Continue Reading
Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal…
Continue Reading
